Weekly weight-loss drug improves sleep apnea in trials
Researchers found a new weekly injection reduced sleep apnea symptoms in two large late-stage clinical trials involving overweight adults.
Scientists tested retatrutide in patients with and without diabetes who had moderate to severe breathing interruptions during their nightly rest periods. The study compared three different weekly doses against a placebo to measure effectiveness across diverse groups.
After eighty weeks, all tested doses lowered breathing pauses compared to the control group, showing consistent results regardless of diabetes status. Participants taking higher amounts saw their condition improve significantly with fewer disruptions throughout the sleep cycle.
This medication works by activating three hormone receptors to lower blood sugar and increase energy burning in the body. Its unique triple action helps reduce body weight while simultaneously addressing the root causes of obstructive sleep apnea.
Many patients no longer needed breathing masks after treatment, as their apnea eased to mild levels without excessive daytime tiredness. The findings suggest this approach could help more people manage their weight and sleep health effectively.